Monte Rosa Therapeutics (NASDAQ:GLUE) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Monte Rosa Therapeutics (NASDAQ:GLUE) from a hold rating to a sell rating in a research report report published on Saturday morning.

A number of other analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Guggenheim decreased their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a report on Wednesday, January 14th. Zacks Research downgraded Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 4th. Finally, TD Cowen reissued a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.80.

Monte Rosa Therapeutics Trading Down 3.8%

Shares of NASDAQ:GLUE opened at $15.03 on Friday. Monte Rosa Therapeutics has a twelve month low of $3.50 and a twelve month high of $25.77. The company’s 50 day moving average is $19.45 and its 200 day moving average is $15.05. The company has a market cap of $1.20 billion, a PE ratio of -32.67 and a beta of 1.63.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). Monte Rosa Therapeutics had a negative return on equity of 15.12% and a negative net margin of 31.23%.The business had revenue of $2.78 million for the quarter, compared to analysts’ expectations of $17.09 million. Equities research analysts predict that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Monte Rosa Therapeutics

In related news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $17.92, for a total value of $97,950.72. Following the completion of the transaction, the chief executive officer directly owned 613,471 shares in the company, valued at $10,993,400.32. The trade was a 0.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Edmund Dunn sold 25,164 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $18.10, for a total transaction of $455,468.40. Following the sale, the insider directly owned 22,693 shares in the company, valued at $410,743.30. This trade represents a 52.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 36,771 shares of company stock valued at $693,692. Company insiders own 6.50% of the company’s stock.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Institutional investors have recently modified their holdings of the business. AQR Capital Management LLC acquired a new position in Monte Rosa Therapeutics in the 1st quarter worth about $1,065,000. Goldman Sachs Group Inc. grew its holdings in Monte Rosa Therapeutics by 122.7% in the first quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock valued at $1,652,000 after purchasing an additional 196,238 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Monte Rosa Therapeutics in the first quarter valued at approximately $76,000. Geode Capital Management LLC increased its position in shares of Monte Rosa Therapeutics by 12.0% in the second quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after buying an additional 120,098 shares in the last quarter. Finally, Intech Investment Management LLC raised its stake in shares of Monte Rosa Therapeutics by 35.4% during the 2nd quarter. Intech Investment Management LLC now owns 29,870 shares of the company’s stock worth $135,000 after buying an additional 7,808 shares during the period. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.